REVIEW article
Front. Nutr.
Sec. Nutrition and Microbes
Volume 12 - 2025 | doi: 10.3389/fnut.2025.1581971
This article is part of the Research TopicFood-Derived Phytochemicals as Regulators of Gut MicrobiotaView all 5 articles
Next-Generation Probiotics and Engineered BEVs for Precision Therapeutics in Osteoporosis
Provisionally accepted
- 1Queen Mary college, Nanchang University, Nanchang, Jiangxi Province, China
- 2Fuzhou Medical College of Nanchang University, Fuzhou, Fujian Province, China
- 3School of Basic Medical Sciences, Nanchang university, Nanchang, Jiangxi Province, China
- 4Third Affiliated Hospital of Nanchang University, Nanchang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Osteoporosis, characterized by reduced bone density and increased fracture risk, faces limitations with conventional therapies due to adverse effects and poor gut microbiota modulation. Emerging strategies leveraging probiotics and bacterial extracellular vesicles (BEVs) offer novel therapeutic potential by targeting the gut-bone axis. Engineered probiotics and next-generation formulations enhance osteoprotection via immunomodulation, metabolite production (e.g., SCFAs), and neuroendocrine regulation. BEVs, as biocompatible nanocarriers, enable targeted delivery of osteogenic factors while circumventing colonization challenges. Synthetic biology advances facilitate precision engineering of probiotics and BEVs, improving therapeutic efficacy and scalability. This review highlights preclinical and clinical progress, challenges in standardization and safety, and future directions for microbiomebased interventions to revolutionize osteoporosis management. Integrating engineered probiotics with BEV technology promises transformative approaches for bone health restoration.
Keywords: Osteoporosis, Probiotics, Gut Microbiota, Bone health, Inflammation, Nextgeneration probiotics, Microbial-targeted therapeutics, Bacterial extracellular vesicles
Received: 23 Feb 2025; Accepted: 11 Jun 2025.
Copyright: © 2025 Wei, Ding, Song, Zhang, Luo and Qi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Qi Luo, School of Basic Medical Sciences, Nanchang university, Nanchang, Jiangxi Province, China
Chan Qi, Third Affiliated Hospital of Nanchang University, Nanchang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.